Q: What happened to the people given the placebo?

They lost weight as well, in every one of these trials, and the size of that movement is the most under-quoted figure in the entire record. Among adults who had both overweight or obesity and type 2 diabetes, estimated change in mean bodyweight from baseline to week 68 was -9·6% (SE 0·4) with semaglutide 2·4 mg vs -3·4% (0·4) with placebo. In the tablet trial, the estimated mean change in body weight from baseline to week 64 was -13.6% in the oral semaglutide group and -2.2% in the placebo group. Those participants kept the same appointments, the same programme and the same questionnaires, and the one thing they did not receive was the compound. A before-and-after pair from one person holds both movements at once with no way to split them, and splitting them is the job the placebo arm was built for.

Q: Was the injection the only thing being given?

It was not, and each trial sets out the rest of the arrangement in its own methods. The 2021 obesity trial assigned its participants to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention. The two-year trial describes both of its arms as receiving the compound or the placebo, both plus behavioral intervention. The 2024 east Asian trial randomised its participants to the injection or the placebo plus a diet and physical activity intervention. So a published percentage is the joint product of an injection, a programme, a clinic and a year of booked appointments, measured against the same arrangement minus the injection. The gap between the arms is the share that belongs to the compound, and the headline percentage is not that share.

Q: Is any of this a measurement of how someone looks?

Only at one remove, through a tape measure and a questionnaire. The 2025 trial listed change in waist circumference (cm) among its confirmatory secondary endpoints, which is the nearest thing here to a measure of shape. The tablet trial recorded the change in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score, a questionnaire about how well people move rather than how they look to anyone. No trial among the sources covered here recorded facial appearance, skin or body proportions as an endpoint, so the questions readers ask about a changed face have no measured answer, and what is documented about them is taken up at the Semaglutide overview. A waist reading and a photograph are different questions, and only the first was taken on a fixed date against a comparison group.

Q: How much of a published figure depends on staying on it?

More than the headline suggests, and the trials are candid about how they counted. The 2021 obesity trial worked its headline number out with the people who had stopped still inside the count, because its main analysis assessed effects regardless of treatment discontinuation or rescue interventions. That is the honest arrangement, and it means the number does not describe only the participants who held on. Inside the trials most people did, since the two-year study randomised 304 participants, 92.8% of whom completed the trial. Who left, and why, is the part that travels to a reader: in the 2017 diabetes trial, 13% of those given the lower weekly amount and 11% of those given a placebo stopped early, and the main reason was gut side effects such as nausea. People were leaving over how the compound felt rather than over what the scale was showing.

Q: Do the figures hold up outside a trial?

They shrink. A 2025 review of routine care says so plainly, reporting that in real-life practice, GLP-1RAs are often less effective than in clinical trial conditions. It names the reason instead of leaving it open. Real-world data shows that many patients use lower doses and do not stick to their treatment as strictly as participants in a controlled trial might, leading to less weight loss. The same review frames it as a clash of settings, since how these medications perform in real life can be different from the controlled settings of clinical trials, in which patients are carefully selected and their treatment plans closely followed. A 2024 review of blood-level data in people adds one more reason to differ, noting that body weight may affect semaglutide exposure, but further studies are needed to confirm this. The gap is selection, amount and sticking with it.

Question 1

What did the trials actually write down as a result?

Accepted Answer

A result, in this literature, is a number taken at a visit somebody scheduled before anyone enrolled. In the 2021 obesity trial, the coprimary end points were the percentage change in body weight and weight reduction of at least 5%. That is a percentage and a yes-or-no threshold, not a description of how a person looked. The 2025 tablet trial counted further up the same scale, since its confirmatory secondary end points included reductions in body weight of 10% or more, 15% or more, and 20% or more. The 2017 diabetes trial measured something else again, because the primary endpoint was the change in mean HbA1c from baseline to week 30, a blood sugar marker. A percentage, a threshold and a blood marker are the whole instrument list.

Question 2

What is in a trial figure that a photograph does not have?

Accepted Answer

Four things, and a picture carries none of them: a weight recorded before anything began, a group of comparable people who were not given the compound, an instrument fixed in advance, and a reading date fixed in advance. In the 2021 obesity trial the investigators enrolled 1961 adults with a body-mass index of 30 or greater, then split them in a 2:1 ratio between the compound and a placebo. Every figure that trial prints is therefore a difference between two groups rather than a change inside one. The tablet work was built the same way, being a 71-week, double-blind, randomized, placebo-controlled trial conducted at 22 sites in four countries. A photograph carries none of the four, which makes it unreadable as a result rather than dishonest, because nobody can ask what those same months would have produced with no injection in them.

Question 3

How soon do the published readings begin?

Accepted Answer

This is the most asked question about semaglutide results, and the record answers it awkwardly, because the readings were scheduled late. A 2024 trial recruited in China, Hong Kong, Brazil and South Korea reports that estimated mean percentage change in bodyweight from baseline to week 44 was -12·1% (SE 0·5) with semaglutide 2·4 mg versus -3·6% (0·7) with placebo. Week 44 is the earliest headline figure it carries. The 2025 trial of a higher weekly amount ran for 72 weeks before its coprimary reading, and the longest trial recorded the mean change in body weight from baseline to week 104. None of that was built to describe a first month, so a one-month figure does not exist to be quoted rather than existing and disappointing. Every published percentage describes people still enrolled most of a year later.

Question 4

Who was weighed in these trials?

Accepted Answer

Every percentage here belongs to a described group, and the descriptions are narrower than the figures that travel out of them. In the two-year trial, most participants were female (236 (77.6%)) and white (283 (93.1%)), with a mean (s.d.) age of 47.3 (11.0) years, body mass index of 38.5 (6.9) kg m-2 and weight of 106.0 (22.0) kg. The 2025 trial gathered a similar group starting heavier, where 1037 (73·7%) of 1407 participants were female, the mean age was 47 (SD 12) years, mean bodyweight was 113·0 (24·1) kg, and mean BMI was 39·9 (7·1) kg/m2. A reader who is male, older, lighter at the start, or managing type 2 diabetes is reading a number measured in somebody else, which is not a reason to discard the figure so much as the first comparison anybody should make against it.

Question 5

Why do the trials report proportions as well as averages?

Accepted Answer

Because the response spread across a wide range, and a mean hides the spread. Alongside its average, the two-year trial records that more participants in the semaglutide group than in the placebo group achieved weight loss ≥5% from baseline at week 104 (77.1% versus 34.4%; P < 0.0001). Read the first of those numbers carefully, because its complement is that roughly a quarter of the participants given semaglutide for two years did not reach a five per cent reduction at all. The 2025 trial counted the other end of the spread, listing the proportion of participants with bodyweight reductions of 10% or greater, 15% or greater, 20% or greater, and 25% or greater versus placebo. Trials publish bands like that because their own participants did not land in one place, which is the plainest statement available that a group mean is not a personal forecast.

Question 6

What happened to the people given the placebo?

Accepted Answer

They lost weight as well, in every one of these trials, and the size of that movement is the most under-quoted figure in the entire record. Among adults who had both overweight or obesity and type 2 diabetes, estimated change in mean bodyweight from baseline to week 68 was -9·6% (SE 0·4) with semaglutide 2·4 mg vs -3·4% (0·4) with placebo. In the tablet trial, the estimated mean change in body weight from baseline to week 64 was -13.6% in the oral semaglutide group and -2.2% in the placebo group. Those participants kept the same appointments, the same programme and the same questionnaires, and the one thing they did not receive was the compound. A before-and-after pair from one person holds both movements at once with no way to split them, and splitting them is the job the placebo arm was built for.

Question 7

Was the injection the only thing being given?

Accepted Answer

It was not, and each trial sets out the rest of the arrangement in its own methods. The 2021 obesity trial assigned its participants to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention. The two-year trial describes both of its arms as receiving the compound or the placebo, both plus behavioral intervention. The 2024 east Asian trial randomised its participants to the injection or the placebo plus a diet and physical activity intervention. So a published percentage is the joint product of an injection, a programme, a clinic and a year of booked appointments, measured against the same arrangement minus the injection. The gap between the arms is the share that belongs to the compound, and the headline percentage is not that share.

Question 8

Is any of this a measurement of how someone looks?

Accepted Answer

Only at one remove, through a tape measure and a questionnaire. The 2025 trial listed change in waist circumference (cm) among its confirmatory secondary endpoints, which is the nearest thing here to a measure of shape. The tablet trial recorded the change in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score, a questionnaire about how well people move rather than how they look to anyone. No trial among the sources covered here recorded facial appearance, skin or body proportions as an endpoint, so the questions readers ask about a changed face have no measured answer, and what is documented about them is taken up at the Semaglutide overview. A waist reading and a photograph are different questions, and only the first was taken on a fixed date against a comparison group.

Question 9

How much of a published figure depends on staying on it?

Accepted Answer

More than the headline suggests, and the trials are candid about how they counted. The 2021 obesity trial worked its headline number out with the people who had stopped still inside the count, because its main analysis assessed effects regardless of treatment discontinuation or rescue interventions. That is the honest arrangement, and it means the number does not describe only the participants who held on. Inside the trials most people did, since the two-year study randomised 304 participants, 92.8% of whom completed the trial. Who left, and why, is the part that travels to a reader: in the 2017 diabetes trial, 13% of those given the lower weekly amount and 11% of those given a placebo stopped early, and the main reason was gut side effects such as nausea. People were leaving over how the compound felt rather than over what the scale was showing.

Question 10

Do the figures hold up outside a trial?

Accepted Answer

They shrink. A 2025 review of routine care says so plainly, reporting that in real-life practice, GLP-1RAs are often less effective than in clinical trial conditions. It names the reason instead of leaving it open. Real-world data shows that many patients use lower doses and do not stick to their treatment as strictly as participants in a controlled trial might, leading to less weight loss. The same review frames it as a clash of settings, since how these medications perform in real life can be different from the controlled settings of clinical trials, in which patients are carefully selected and their treatment plans closely followed. A 2024 review of blood-level data in people adds one more reason to differ, noting that body weight may affect semaglutide exposure, but further studies are needed to confirm this. The gap is selection, amount and sticking with it.

Question 11

Can semaglutide reviews and posted accounts be read as results?

Accepted Answer

They can be read as experience, which is real, and not as a result, which is a much narrower object. A posted account has no starting weight from a clinic scale, nobody comparable standing beside it untreated, no reading date set in advance, and no record of what else changed over the same months. It also arrives through a filter nobody controls, since people who stop early are the least likely to post a twelve-month update. A 2022 meta-analysis covering 4 randomized controlled trials having a total of 3,613 individuals with obesity without diabetes found that risk of gastrointestinal adverse events, discontinuation of treatment and serious adverse events were higher in the semaglutide group versus placebo. Counting posts is not the same as counting participants, and the two sources answer different questions.

Question 12

Do the published figures belong to a compounded vial?

Accepted Answer

Not automatically, and two FDA enforcement records show why the question is not pedantry. A 2025 Class II action covers Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy, recalled under the stated reason Subpotent Drug, meaning the vial carried less of the compound than its label declared. A second 2025 action, from a different pharmacy, covers a preparation sold as Semaglutide +Cyanocobalamin and recalled for Lack of Processing Controls, so a second ingredient was sitting in the vial beside the first. A percentage produced by a vial of uncertain strength, or by a mixture of two things, cannot be matched against a trial that gave a measured amount of one compound to a counted group. What is on record about those products sits at the Semaglutide sourcing page.

Question 13

What happens to the result when the injection stops?

Accepted Answer

This is where an enormous record thins, and the thinness is itself the finding. A 2025 review of routine care puts studies of the effects of stopping GLP-1RA treatment on its own list of work still to do. It also emphasizes the need for more research to understand why many patients stop using these medications and how to improve dosing. A 2024 review in Diabetes Care writes about regain in the conditional rather than the past tense, merely proposing that retaining lean mass during incretin therapy could blunt body weight (and fat) regain on cessation of weight loss pharmacotherapy. For comparison, a 2023 review of obesity care in adults reports that with diet and behaviour programmes alone, weight regain occurs in 25% or more of participants at 2-year follow-up. That figure belongs to those programmes rather than to this compound, and no trial among the studies covered here walked participants through a planned stop.

Semaglutide: reported results by outcome